Navigation Links
Newer Blood Pressure Drug Better for Some Heart Patients, Diabetics
Date:8/31/2008

Study found telmisartan offered slight benefit for those unable to take ACE inhibitors

SUNDAY, Aug. 31 (HealthDay News) -- A new study offers a possible alternative to heart patients and diabetics who need to keep their blood pressure under control but who cannot tolerate the standard treatment of ACE inhibitors.

Reporting at the European Society of Cardiology in Munich on Sunday, Canadian researchers said they found that the angiogenesis-receptor blocker (ARB) known as telmisartan worked well for the 20 percent of patients with vascular disease and high-risk diabetes who can't take ACE inhibitors. The study was released in the Aug. 31 online issue of The Lancet to coincide with the meeting presentation.

In the randomized, controlled trial, almost 6,000 patients with vascular disease or high-risk diabetes took either telmisartan or a placebo, and were followed for almost five years. Rates of death, heart attack, stroke or hospitalization for heart failure were tracked as primary outcome measures during the study period.

Mean blood pressure was lower in the telmisartan group by 4.0/2.2 mm/Hg, and there was a relative risk reduction of 13.3 percent for those taking telmisartan. Fewer patients on the medication wound up in the hospital for cardiovascular problems (30.3 percent), compared to those on placebo (33 percent).

"These data suggest that telmisartan confers a modest benefit when added to other proven therapies," the researchers wrote in a news release from the journal. "In view of the drug's tolerability and effect on cardiovascular endpoints, telmisartan could be regarded as a potential treatment for patients with vascular disease or high-risk diabetes, if they are unable to tolerate an ACE inhibitor."

However, an accompanying commentary from U.S. experts dampened the significance of the finding.

"ARBs that have been studied in coronary disease are safe, but possibly less effective alternatives in patients with intolerance to ACE inhibitors. Although data are too limited to reach definitive conclusions, the clinical effect of ARBs seems less robust than that of ACE inhibitors," wrote Dr. Toni Ripley and Dr. Donald Harrison, from the University of Oklahoma College of Pharmacy.

And U.S. researchers reported on Wednesday that telmisartan does not lower the rate of stroke, cardiovascular events or diabetes better than a placebo in patients who have had a stroke.

More information

For more on ARBs, go to U.S. Food and Drug Administration.



-- HealthDay staff



SOURCE: The Lancet, news release, Aug. 31, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke
2. Newer Prostate Cancer Treatment Similar to Traditional Surgery
3. Newer Rheumatoid Arthritis Drugs Lower Production of B Cells
4. Newer Sedative Might Help Patients on Ventilators
5. Newer Anticlotting Drug Safe, Effective for Heart Surgeries
6. Newer radiation treatment easier for some throat cancer patients
7. Newer Antibiotic Speeds TB Healing
8. Newer antidepressants led to less, not more, teen suicides
9. Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose
10. Finding May Allow Some Women to Stop Blood Thinners
11. For Rare Blood Disorder, Pumping Iron Is the Cure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Blood Pressure Drug Better for Some Heart Patients, Diabetics
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is ... than filling out a survey; in many cases health professionals and patients are working ... and research on the importance of active engagement with patients and members of the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... process to promote standards of excellence for the field of eating disorders, announces ... 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to host ... items from across the nation, this holiday-themed event will raise funds and awareness for ... The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 p.m.) ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers were ... innovative way to use nonlinear optical imaging to confirm ... drugs. A ... show how researchers from BioPharmX and the Wellman Center ... a suite of imaging techniques in what is called ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
Breaking Medicine Technology: